## **Supplement Figures**

Title: Optimal Duration of Dual Antiplatelet Therapy for Minor Stroke Within 72 Hours of Symptom Onset: A Prospective Cohort Study

List of Supplemental Figures

sFigure 1 Curvilinear Relationship between Antiplatelet Duration and Primary Outcome.

A. Curvilinear Relationship between DAPT Duration and Primary Outcome; B. Curvilinear Relationship between SAPT Duration and Primary Outcome.


sFigure 2 Hazard Ratio for the Primary Outcome in Subgroups for Entire Population.

sFigure 3 Hazard Ratio for the Primary Outcome in Subgroups for Population with Shorter Duration (< 10 days) of DAPT Compared with SAPT Group.

sFigure 4 Hazard Ratio for the Primary Outcome in Subgroups for for Population with Long Duration (> 21 days) of DAPT Compared with SAPT Group.

sFigure 5 Cumulative Probability of Primary Events in Four Secondary Therapies.

sFigure 1 Curvilinear Relationship between Antiplatelet Duration and Primary Outcome.



Subgroup	No. of Patients	SAPT no. of pat	DAPT tients (%)	HR (95%CI)		P for interaction
Overall						
Crude	2977	103(8.9)	154(8.5)		0.96 (0.75~1.33)	<b>.8</b> 3
IPTW	2955	124(10.4)	153(8.7)		0.90 (0.68~1.21)	.50
Age,y						.95
<65	1799	52 (8.9)	105 (8.6)	<b>⊢</b> _	0.96 (0.69~1.35)	
≥65	1178	51 (8.8)	49 (8.2)	<b>⊢</b>	0.95 (0.64~1.41)	
Gender						.84
Female	594	32 (9.0)	40 (9.1)	¢4	1.04 (0.65~1.67)	
Male	2183	71 (8.8)	114 (8.3)	<b>⊢</b> 4	0.96 (0.72~1.3)	
Smoking						.57
Never	1420	47 (7.6)	72 (9.0)	P	1.17 (0.81~1.69)	
Previous	182	12 (16.9)	11 (9.9)	<b>F</b>	0.63 (0.27~1.44)	
Current	1286	38 (8.8)	64 (7.5)	P	0.85 (0.57~1.27)	
Histroy of Hypertension						.39
No	1173	38 (8.7)	54 (7.3)	<b>▶</b> ∎	0.86 (0.57~1.31)	
Yes	1804	65 (9)	100 (9.3)	<b>⊢</b>	1.06 (0.78~1.45)	
Previous diabetes						.52
No	2185	60 (7.2)	99 (7.3)	<b>⊢</b>	1.05 (0.76~1.45)	
Yes	792	43 (13.2)	55 (11.8)	<b>▶∎</b> 4	0.89 (0.60~1.33)	
Previous Dyslipidemia		. ,	. ,		, , , , , , , , , , , , , , , , , , ,	.96
No	2908	99 (8.7)	147 (8.3)	<b>⊢</b> ∎-4	0.97 (0.75~1.25)	
Yes	69	4 (16.7)	7 (15.6)	<b>⊢</b>	→ 0.92 (0.27~3.13)	
Previous ischemic stroke	)					.52
No	2301	70 (8.2)	114 (7.9)	<b>▶8</b> 4	0.94 (0.7~1.26)	
Yes	676	33 (10.6)	40 (8.7)	F	1.09 (0.68~1.73)	
rior antiplatelet		. ,	. ,		, , , , , , , , , , , , , , , , , , ,	.19
No	2632	85 (8.4)	140 (8.7)	<b>⊢</b> _	1.03 (0.78~0.1.34)	
Yes	336	16 (11.3)	14 (7.2)	<b></b>	0.67 (0.32~1.39)	
CAS		. ,	. ,		, , , , , , , , , , , , , , , , , , ,	.58
No	1712	34 (5.5)	72 (6.6)	<b>⊢</b>	1.19 (0.79~1.79)	
Yes	1188	66 (13.3)	80 (11.6)	<b>▶</b> — <b>■</b> —	0.79 (0.65~1.25)	
OAST Classification						.33
LAA	899	49 (13.1)	56 (10.6)	<b>▶∎</b> 4	0.84 (0.57~1.24)	
SVO	1369	26 (5.4)	56 (6.3)	<b>•</b>	1.17 (0.73~1.86)	
OE	50	6 (27.3)	4 (14.3)		0.47 (0.13~1.66)	
UD	659	22 (7.8)	38 (10.1)		1.3 (0.77~2.21)	
Similar RCT population		()	50 (10.1)			.96
No	1163	57 (8.2)	75 (8.0)	<b></b>	0.94 (0.67~1.34)	
Yes	1342	46 (9.9)	79 (9.0)		0.94 (0.65~1.36)	
	1072	10 (0.0)	, 0 (0.0)		0.04 (0.00/~1.00)	

## sFigure 2 Hazard Ratio for the Primary Outcome in Subgroups for Entire Population.

sFigure 3 Hazard Ratio for the Primary Outcome in Subgroups for Population with Shorter Duration (< 10

days) of DAPT Compared with SAPT Group	p.
--	----

Subgroup	No. of	SAPT	DAPT	HR (95%CI)	P for interaction
	Patients	no. of pa	tients (%)		
Overall					
Crude	1468	103(8.9)	31(10.2)	1.2 (0	0.8~1.8) .37
IPTW	1329	105(8.5)	9(9.3)	1.14	(0.57,2.29) .70
Age,y					.46
<65	778	52 (8.9)	22 (11.3)	1.34 (	(0.81~2.2)
>=65	691	51 (8.8)	9 (8.1)	•• 0.95 (	(0.47~1.94)
Gender					.38
Female	437	32 (9)	11 (13.4)	▶ 1.59 (	(0.8~3.16)
Male	1031	71 (8.8)	20 (9)	▶── <b>■</b> ───↓ 1.06 (	(0.64~1.74)
Smoking					.91
Never	754	47 (7.6)	13 (9.6)	<b>⊢</b> ∎ 1.28 (	(0.69~2.36)
Previous	95	12 (16.9)	3 (12.5)	▶ 0.78 (	(0.22~2.81)
Current	569	38 (8.8)	13 (9.6)	<b>⊢</b> ∎ 1.14 (	(0.61~2.14)
Histroy of Hypertension	I				.62
No	562	38 (8.7)	14 (11.2)	<b>⊢ ■</b> 1.37 (	(0.74~2.54)
Yes	906	65 (9)	17 (9.4)	<b>⊢</b> 1.09 (	(0.64~1.86)
Previous diabetes					.55
No	1069	60 (7.2)	21 (9.1)	1.35	(0.82~2.22)
Yes	399	43 (13.2)	10 (13.5)	<b>⊢−−−</b> ∎−−−−− 1.05 (	(0.53~2.08)
Previous Dyslipidemia					.73
No	1437	99 (8.7)	30 (10.1)	1.22 (	(0.81~1.83)
Yes	31	4 (16.7)	1 (14.3)	▶ 0.82 (	(0.09~7.3)
Previous ischemic strok	æ				.52
No	1086	70 (8.2)	21 (9)	1.13 (	(0.69~1.84)
Yes	382	33 (10.6)	10 (14.1)	▶ 1.46 (	(0.72~2.97)
Prior antiplatelet					.54
No	1288	85 (8.4)	28 (10.3)	1.29 (	(0.84~1.98)
Yes	175	16 (11.3)	3 (8.8)	▶ 0.83 (	(0.24~2.87)
ICAS					.40
No	801	34 (5.5)	15 (8.1)	► <b>• • • • • • • • • • • • • • • • • • •</b>	0.82~2.75)
Yes	604	66 (13.3)	14 (13)	1.04 (	(0.58~1.85)
TOAST Classification					.56
LAA	449	49 (13.1)	12 (15.8)	<b>▶</b> 1.31 (	(0.69~2.47)
SVO	636	26 (5.4)	7 (4.6)	0.86 (	(0.37~1.98)
OE	28	6 (27.3)	2 (33.3)	► <b>1</b> .37 (	(0.28~6.81)
UD	355	22 (7.8)	10 (13.9)		(0.92~4.1)
Similar RCT population		-	-		.72
No	846	57 (8.2)	13 (8.7)	<b>└────↓</b> 1.1 (0	0.6~2.01)
Yes	622	46 (9.9)	18 (11.5)		(0.72~2.14)

DAPT better SAPT better

sFigure 4 Hazard Ratio for the Primary Outcome in Subgroups for for Population with Long Duration (> 21

days) of DAPT Compared with SAPT Group.

	No. of Patients	SAPT <sup>∋</sup> no. of pa	DAPT tients (%)	HR (95%CI)	P for interactio
Overall		· ·	,		
Crude	1735	103(8.9)	59(10.4)	1.2 (0.87~	1.65) .27
IPTW	1727	102(8.6)	5 <b>8(10.3)</b>	1.22 (0.88	•
Age,y		· · ·	. ,		.85
<65	960	52 (8.9)	40 (10.6)	<b>■</b> 1.23 (0.81~ <sup>-</sup>	1.86)
>=65	775	51 (8.8)	19 (9.7)	<b>Ⅰ</b> 1.13 (0.67~	1.92)
Gender					.36
Female	490	32 (9)	11 (8.1)	▶	1.83)
Male	1245	71 (8.8)	48 (11)	<b>1.29 (0.89∼</b>	1.86)
Smoking					.32
Never	871	47 (7.6)	27 (10.7)	▶ 1.41 (0.88~2	2.27)
Previous	118	12 (16.9)	3 (6.4)	▶ ■ 0.4 (0.11~1.	44)
Current	692	38 (8.8)	27 (10.5)	<b>■</b> 1.21 (0.74~	1.98)
Histroy of Hypertension					.16
No	663	38 (8.7)	17 (7.5)	0.88 (0.5~1.	56)
Yes	1072	65 (9)	42 (12.1)	<b>▶</b> 1.41 (0.95~2	2.08)
Previous diabetes		.,	. ,		.69
No	1252	60 (7.2)	36 (8.7)	▶ 1.27 (0.84~	1.92)
Yes	483	43 (13.2)	23 (14.6)	<b>Ⅰ</b> 1.11 (0.67~	
Previous Dyslipidemia					.35
No	1696	99 (8.7)	54 (9.7)	<b>▶</b> 1.15 (0.82~ <sup>-</sup>	1.6)
Yes	39	4 (16.7)	5 (33.3)	▶ 2.08 (0.56~	
Previous ischemic stroke					.17
No	1299	70 (8.2)	49 (11)	<b>■</b> 1.37 (0.95~ <sup>-</sup>	1.97)
Yes	436	33 (10.6)	10 (8)	•    ••   • •   •    •	
Prior antiplatelet					.27
No	1505	85 (8.4)	52 (10.7)	▶ 1.31 (0.92~	1.84)
Yes	223	16 (11.3)	7 (8.5)	▶ ● 0.8 (0.33~1.	96)
ICAS					.40
No	921	34 (5.5)	26 (8.5)	▶ 1.57 (0.94~2	2.61)
Yes	745	66 (13.3)	32 (12.9)	<b>▶</b> 0.99 (0.65~	1.52)
TOAST Classification					.15
LAA	585	49 (13.1)	25 (11.8)	<b>▶ ■ 0.93 (0.57~</b>	1.5)
SVO	739	26 (5.4)	20 (7.9)	▶ 1.49 (0.83~2	
OE	33	6 (27.3)	1 (9.1)	• 0.29 (0.03~2	2.41)
UD	378	22 (7.8)	13 (13.7)	▶ 1.82 (0.92~	
Similar RCT population				, , , , , , , , , , , , , , , , , , ,	.34
No	995	57 (8.2)	33 (11.1)	<b>→</b> 1.39 (0.9~2.	
Yes	740	46 (9.9)	26 (9.5)	●● 0.99 (0.61~	,

## sFigure 5 Cumulative Probability of Primary Events in Four Secondary Therapies.

